ERBB2 and hepatocellular carcinoma: To further investigate the impact of ERBB2 inhibitor (afatinib) on the prognosis of HCC, we analyzed the Kaplan-Meier Plotter data and found that HCC patients with high ERBB2 expression had significantly lower recurrence free survival (RFS) and progression-free survival (PFS) than those with low or no expression (Figure 3C).